Illumina, Inc. vs MGM Resorts International — how do they compare? Illumina, Inc. trades at $264.95 (market cap $39.95B), while MGM Resorts International trades at $30.16 (market cap $7.55B). The key difference: Illumina, Inc. is far larger — about 5.3× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and MGM Resorts International for 91 Days on average.
| ILMN | MGM | |
|---|---|---|
Market Cap | $39.95B | $7.55B |
Volume | 3,169,503 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $50.69 |
52-Week Low | $91.00 | $30.00 |
Typical Hold Time | 83 Days | 91 Days |
Enterprise Value | $41.31B | $34.85B |
Dividend Yield | — | 0.03% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day, reflecting recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock is technically bearish with key support at $29, while fundamentals show mixed signals: revenue growth is steady but net income margin has compressed to 2.4% in 2025. Analyst consensus remains bullish with a $48.75 price target, though near-term sentiment is pressured by deal uncertainty.
The outlook hinges on MGM's ability to stabilize earnings and potentially pursue strategic alternatives like a bid for People Inc. Upside exists if management executes on value-unlocking initiatives, but risks include integration challenges, high debt levels, and macroeconomic sensitivity. The current price offers a discount to analyst targets, presenting a contrarian opportunity amid weak sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →